BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 21406197)

  • 1. Induction of the fibrinolytic system by cartilage extract mediates its antiangiogenic effect in mouse glioma.
    Simard B; Bouamrani A; Jourdes P; Pernod G; Dimitriadou V; Berger F
    Microvasc Res; 2011 Jul; 82(1):6-17. PubMed ID: 21406197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-type plasminogen activator has antiangiogenic properties without effect on tumor growth in a rat C6 glioma model.
    Solly F; Fish R; Simard B; Bolle N; Kruithof E; Polack B; Pernod G
    Cancer Gene Ther; 2008 Oct; 15(10):685-92. PubMed ID: 18535615
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shark cartilage extract induces cytokines expression and release in endothelial cells and induces E-selectin, plasminogen and t-PA genes expression through an antioxidant-sensitive mechanism.
    Simard B; Ratel D; Dupré I; Pautre V; Berger F
    Cytokine; 2013 Jan; 61(1):104-11. PubMed ID: 23063000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination angiostatin and endostatin gene transfer induces synergistic antiangiogenic activity in vitro and antitumor efficacy in leukemia and solid tumors in mice.
    Scappaticci FA; Smith R; Pathak A; Schloss D; Lum B; Cao Y; Johnson F; Engleman EG; Nolan GP
    Mol Ther; 2001 Feb; 3(2):186-96. PubMed ID: 11237675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasminogen kringle 5-engineered glioma cells block migration of tumor-associated macrophages and suppress tumor vascularization and progression.
    Perri SR; Nalbantoglu J; Annabi B; Koty Z; Lejeune L; François M; Di Falco MR; Béliveau R; Galipeau J
    Cancer Res; 2005 Sep; 65(18):8359-65. PubMed ID: 16166313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site.
    Ahn JH; Lee HJ; Lee EK; Yu HK; Lee TH; Yoon Y; Kim SJ; Kim JS
    Biol Chem; 2011 Apr; 392(4):347-56. PubMed ID: 21194375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiostatin suppresses malignant glioma growth in vivo.
    Kirsch M; Strasser J; Allende R; Bello L; Zhang J; Black PM
    Cancer Res; 1998 Oct; 58(20):4654-9. PubMed ID: 9788618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of simvastatin on cigarette smoke extract induced tissue-type plasminogen activator and plasminogen activator inhibitor-1 expression in human umbilical vein endothelial cells.
    Hu XY; Ma YH; Wang C; Yang YH
    Chin Med J (Engl); 2009 Oct; 122(19):2380-5. PubMed ID: 20079143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
    Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
    Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody-directed targeting of angiostatin's receptor annexin II inhibits Lewis Lung Carcinoma tumor growth via blocking of plasminogen activation: possible biochemical mechanism of angiostatin's action.
    Sharma MR; Rothman V; Tuszynski GP; Sharma MC
    Exp Mol Pathol; 2006 Oct; 81(2):136-45. PubMed ID: 16643891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
    Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
    Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
    Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
    Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis.
    Inoue M; Sawada T; Uchima Y; Kimura K; Nishihara T; Tanaka H; Yashiro M; Yamada N; Ohira M; Hirakawa K
    Oncol Rep; 2005 Dec; 14(6):1445-51. PubMed ID: 16273237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo induction of antiangiogenic activity by plasminogen activators and captopril.
    Merchan JR; Chan B; Kale S; Schnipper LE; Sukhatme VP
    J Natl Cancer Inst; 2003 Mar; 95(5):388-99. PubMed ID: 12618504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoids induced t-PA synthesis by C6 glioma cells--role in tumoral haemorrhagic necrosis.
    Pernod G; Amalfitano G; Le Magueresse B; Berger F; Polack B; Kolodié L
    Thromb Haemost; 1996 Feb; 75(2):332-8. PubMed ID: 8815586
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine.
    Albini A; Morini M; D'Agostini F; Ferrari N; Campelli F; Arena G; Noonan DM; Pesce C; De Flora S
    Cancer Res; 2001 Nov; 61(22):8171-8. PubMed ID: 11719447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA.
    Tanaka T; Cao Y; Folkman J; Fine HA
    Cancer Res; 1998 Aug; 58(15):3362-9. PubMed ID: 9699667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravital microscopy reveals novel antivascular and antitumor effects of endostatin delivered locally by alginate-encapsulated cells.
    Read TA; Farhadi M; Bjerkvig R; Olsen BR; Rokstad AM; Huszthy PC; Vajkoczy P
    Cancer Res; 2001 Sep; 61(18):6830-7. PubMed ID: 11559558
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The therapeutic efficacy of angiostatin against weakly- and highly-immunogenic 3LL tumors.
    Li M; Huang X; Zhu Z; Zhao Q; Wong M; Gorelik E
    In Vivo; 2002; 16(6):577-82. PubMed ID: 12494903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
    Munkvad S
    Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.